Ranolazine

Nature Reviews Drug Discovery

Volumn 5, Issue 6, 2006, Pages 453-454

  Abrams, Jonathan ^a   Jones, Carole A ^b   Kirkpatrick, Peter ^c  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b IQVIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; ANTIANGINA PECTORIS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; GLYCERYL TRINITRATE; IVABRADINE; LONG ACTING DRUG; METOPROLOL; METOPROLOL SUCCINATE; NICORANDIL; NITRATE; NITRIC ACID DERIVATIVE; PLACEBO; RANOLAZINE; CALCIUM; PIPERAZINE DERIVATIVE; SODIUM;

BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG STRUCTURE; EUROPE; FOOD AND DRUG ADMINISTRATION; FRANCE; GERMANY; HEADACHE; HUMAN; ITALY; LETHARGY; NOTE; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; SPAIN; STABLE ANGINA PECTORIS; SYMPTOM; UNITED KINGDOM; UNITED STATES; ANGINA PECTORIS; ARTICLE; CONTROLLED CLINICAL TRIAL; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

ANGINA PECTORIS; CALCIUM; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS; SODIUM;

EID: 33745952247     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2069     Document Type: Note

References (11)

1. Abrams, J. Chronic stable angina. N. Engl. J. Med. 352, 2524-2533 (2005).
2. Gibbons, R. J. et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina) [online], (2002).
3. Gaffney, S. M. Ranolazine, a novel agent for chronic stable angina. Pharmacotherapy 26, 135-142 (2006).
4. Chaitman, B. R. et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43, 1375-1382 (2004).
5. Chaitman, B. R. et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 291, 309-316 (2004).
6. FDA labelling information [online], < http://www.fda.gov/cder/foi/label/2006/021526s000lbl.pdf> (2006).
7. Antzelevitch, C. et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110, 904-910 (2004).
8. Makielski, J. C. & Valdivia, C. R. Ranolazine and late cardiac sodium current - a therapeutic target for angina, arrythmia and more. Brit. J. Pharmacol. 148, 4-6 (2006).
9. Conti, C. R. Inhibition of sodium-dependent calcium overload to treat myocardial ischemia. Clin. Cardiol. 29, 141-143 (2006).
10. Heart Disease and Stroke Statistics - 2006 Update [online], (2006).
11. IMS Health, MIDAS Quantum data (2005).